Cargando…

Formyl peptide receptor 2 determines sex-specific differences in the progression of nonalcoholic fatty liver disease and steatohepatitis

Nonalcoholic fatty liver disease (NAFLD) is an important health concern worldwide and progresses into nonalcoholic steatohepatitis (NASH). Although prevalence and severity of NAFLD/NASH are higher in men than premenopausal women, it remains unclear how sex affects NAFLD/NASH pathophysiology. Formyl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Chanbin, Kim, Jieun, Han, Jinsol, Oh, Dayoung, Kim, Minju, Jeong, Hayeong, Kim, Tae-Jin, Kim, Sang-Woo, Kim, Jeong Nam, Seo, Young-Su, Suzuki, Ayako, Kim, Jae Ho, Jung, Youngmi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8803937/ https://www.ncbi.nlm.nih.gov/pubmed/35102146 http://dx.doi.org/10.1038/s41467-022-28138-6

Ejemplares similares

Potential Therapeutic Application of Estrogen in Gender Disparity of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
por: Lee, Chanbin, et al.
Publicado: (2019)

Hepatoprotective Effect of Kombucha Tea in Rodent Model of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
por: Lee, Chanbin, et al.
Publicado: (2019)

Formyl peptide receptor 2 is an emerging modulator of inflammation in the liver
por: Lee, Chanbin, et al.
Publicado: (2023)

Targeted Deletion of Thymosin Beta 4 in Hepatic Stellate Cells Ameliorates Liver Fibrosis in a Transgenic Mouse Model
por: Kim, Jieun, et al.
Publicado: (2023)

Deficiency of Formyl Peptide Receptor 2 Retards Hair Regeneration by Modulating the Activation of Hair Follicle Stem Cells and Dermal Papilla Cells in Mice
por: Han, Jinsol, et al.
Publicado: (2021)

Mesenchymal Stem Cells Influence Activation of Hepatic Stellate Cells, and Constitute a Promising Therapy for Liver Fibrosis
por: Lee, Chanbin, et al.
Publicado: (2021)

sEVs from tonsil-derived mesenchymal stromal cells alleviate activation of hepatic stellate cells and liver fibrosis through miR-486-5p
por: Kim, Jieun, et al.
Publicado: (2021)

Circulating miRNA is a useful diagnostic biomarker for nonalcoholic steatohepatitis in nonalcoholic fatty liver disease
por: Kim, Tae Hyung, et al.
Publicado: (2021)

The role of hepatic macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
por: Cha, Ji-Young, et al.
Publicado: (2018)

Noninvasive predictors of nonalcoholic steatohepatitis in Korean patients with histologically proven nonalcoholic fatty liver disease
por: Kim, Young Seok, et al.
Publicado: (2013)

Pathological Contribution of Extracellular Vesicles and Their MicroRNAs to Progression of Chronic Liver Disease
por: Lee, Chanbin, et al.
Publicado: (2022)

Use of a Diabetes Self-Assessment Score to Predict Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
por: Kim, Gyuri, et al.
Publicado: (2015)

Discrimination of Nonalcoholic Steatohepatitis Using Transient Elastography in Patients with Nonalcoholic Fatty Liver Disease
por: Lee, Hye Won, et al.
Publicado: (2016)

Fermented ginseng, GBCK25, ameliorates steatosis and inflammation in nonalcoholic steatohepatitis model
por: Choi, Naeun, et al.
Publicado: (2019)

Overexpression of Interleukin-8 Promotes the Progression of Fatty Liver to Nonalcoholic Steatohepatitis in Mice
por: Cho, Ye Eun, et al.
Publicado: (2023)

Ablation of the deubiquitinase USP15 ameliorates nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
por: Baek, Jung-Hwan, et al.
Publicado: (2023)

Apoptosis and diagnosis of nonalcoholic steatohepatitis
por: Kim, Chang Wook, et al.
Publicado: (2011)

MicroRNA-378 is involved in hedgehog-driven epithelial-to-mesenchymal transition in hepatocytes of regenerating liver
por: Kim, Jieun, et al.
Publicado: (2018)

Current Therapeutic Options and Potential of Mesenchymal Stem Cell Therapy for Alcoholic Liver Disease
por: Han, Jinsol, et al.
Publicado: (2022)

Tumor necrosis factor-inducible gene 6 interacts with CD44, which is involved in fate-change of hepatic stellate cells
por: Wang, Sihyung, et al.
Publicado: (2020)

FRI037 Time-restricted Feeding Prevents Progression Of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis Through IPMK
por: Jung, Ik-Rak, et al.
Publicado: (2023)

Pathophysiological Aspects of Alcohol Metabolism in the Liver
por: Hyun, Jeongeun, et al.
Publicado: (2021)

Rodent Models of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
por: Imajo, Kento, et al.
Publicado: (2013)

Considerations for Physiologically Based Modeling in Liver Disease: From Nonalcoholic Fatty Liver (NAFL) to Nonalcoholic Steatohepatitis (NASH)
por: Murphy, William A., et al.
Publicado: (2022)

Nonalcoholic fatty liver disease in obese and nonobese pediatric patients
por: Kim, Eun Jeong, et al.
Publicado: (2019)

Pathogenesis of Nonalcoholic Steatohepatitis and Hormone-Based Therapeutic Approaches
por: Kim, Kook Hwan, et al.
Publicado: (2018)

Detection of Nα-terminally formylated native proteins by a pan-N-formyl methionine-specific antibody
por: Kim, Dasom, et al.
Publicado: (2023)

Gemigliptin, a DPP4 inhibitor, ameliorates nonalcoholic steatohepatitis through AMP-activated protein kinase-independent and ULK1-mediated autophagy
por: Song, Youngmi, et al.
Publicado: (2023)

Targeting of Secretory Proteins as a Therapeutic Strategy for Treatment of Nonalcoholic Steatohepatitis (NASH)
por: Kim, Kyeongjin, et al.
Publicado: (2020)

Genetic Factors in the Pathogenesis of Nonalcoholic Fatty Liver and Steatohepatitis
por: Dongiovanni, Paola, et al.
Publicado: (2015)

Murine Models of Nonalcoholic Fatty Liver Disease and Steatohepatitis
por: Ninomiya, Masashi, et al.
Publicado: (2012)

Magnetic resonance‐based biomarkers in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
por: Caussy, Cyrielle, et al.
Publicado: (2020)

Γ-Aminobutyric acid promotes methionine-choline deficient diet-induced nonalcoholic steatohepatitis
por: Seok Roh, Yoon, et al.
Publicado: (2017)

Noninvasive markers: a double-edged sword that stratifies nonalcoholic steatohepatitis
por: Chung, Goh Eun, et al.
Publicado: (2013)

Development of liver surface nodularity quantification program and its clinical application in nonalcoholic fatty liver disease
por: Kim, Tae-Hoon, et al.
Publicado: (2019)

Rho-Kinase as a Therapeutic Target for Nonalcoholic Fatty Liver Diseases
por: Sousa-Lima, Inês, et al.
Publicado: (2021)

Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH)
por: Drescher, Hannah K., et al.
Publicado: (2019)

Gut microbiota profile in patients with nonalcoholic fatty liver disease and presumed nonalcoholic steatohepatitis
por: Mohammadi, Zahra, et al.
Publicado: (2022)

Circulating Citrate Is Associated with Liver Fibrosis in Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
por: Amjad, Waseem, et al.
Publicado: (2023)

Can Nutritional Supplements Benefit Patients With Nonalcoholic Steatohepatitis and Nonalcoholic Fatty Liver Disease?
por: Baradeiya, Ahmed M, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_63b7qktqgfvvsk0npemm1qf66m